Parnax Lab

Parnax Lab EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Parnax Lab (506128.BO) as of Nov 14, 2026 is 15.19 %. In the previous year, Year-over-Year EBITDA Growth was 2.14 % — a change of 611.11% (higher).

EBITDA Growth YoY

15.19 %

YoY

611.11%

Last updated:

Year-over-Year EBITDA Growth of Parnax Lab is 2025 15.19 % . Year-over-Year EBITDA Growth of Parnax Lab was 2024 2.14 % . It decreases by 611.11% higher compared to the previous year.

The Parnax Lab EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
-12.27 INR
Jan 1, 2019
-8.72 INR
Jan 1, 2020
-37.04 INR
Jan 1, 2021
54.57 INR
Jan 1, 2022
131.54 INR
Jan 1, 2023
0.17 INR
Jan 1, 2024
2.14 INR
Jan 1, 2025
15.19 INR
The Parnax Lab EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
15.19 %+611.11%
2.14 %+1,161.36%
0.17 %-99.87%
131.54 %+141.03%
54.57 %-247.33%
-37.04 %+324.59%
-8.72 %-28.88%
-12.27 %-152.24%
23.48 %-232.00%
-17.79 %-150.70%
35.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Year-over-Year EBITDA Growth of Parnax Lab is 15.19 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Parnax Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Parnax Lab

All Key Metrics — Parnax Lab